Completed PHASE1 INTERVENTIONAL NCT00002746

Interleukin-2 in Treating Patients With Myelodysplastic Syndrome

A PHASE I TRIAL OF SUBCUTANEOUS, OUTPATIENT INTERLEUKIN-2 FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS)

Sponsor: University of Washington

Conditions Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms

Interventions aldesleukin

Updated 6 times since 2017 Last updated: Feb 25, 2019 Started: Jan 31, 1996 Primary completion: Apr 30, 2004 Completion: Apr 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Leukemia and Myelodysplastic Syndromes, this trial is completed. The trial is conducted by University of Washington and has accumulated 6 data snapshots since 1996. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Mar 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Mar 2019 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jan 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Washington

Data source: University of Washington

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seattle, United States